Mercalis and PharmaCord Merge to Form Valeris, Creating Integrated Therapy Commercialization Platform
Key Insights
Mercalis (search) and PharmaCord (search) have officially merged to form Valeris (search), a new entity focused on improving therapy delivery for life sciences companies.
The merger combines Mercalis (search)'s healthcare commercialization expertise with PharmaCord (search)'s patient support services and pharmaceutical distribution capabilities.
Valeris (search) aims to streamline processes that help pharmaceutical companies navigate the complexities of bringing medical therapies from development to patients.
Mercalis (search) and PharmaCord (search) have officially merged to form a new entity named Valeris (search), establishing a comprehensive platform designed to improve how life sciences companies deliver their therapies to market. The rebranding marks a significant step in consolidating the resources and expertise of both organizations under one unified brand.
Strategic Integration of Complementary Capabilities
The newly formed Valeris (search) combines the strengths of Mercalis (search), known for its innovative solutions in healthcare commercialization, and PharmaCord (search), recognized for its patient support services and pharmaceutical distribution capabilities. By integrating their operations, Valeris seeks to streamline processes that assist life sciences companies in navigating the complexities of bringing medical therapies from development stages to patients.
Enhanced Therapy Commercialization Solutions
The merger creates an integrated approach for supporting pharmaceutical companies through the therapy commercialization process. Valeris (search) combines Mercalis (search)'s capabilities with PharmaCord (search)'s established infrastructure, providing a cohesive system that addresses challenges within the pharmaceutical industry while maintaining focus on efficiency and accessibility.
This development is expected to streamline processes and provide enhanced solutions for bringing medical treatments from development stages to patients efficiently. The merger reflects an effort to create a unified platform that can better serve the evolving needs of life sciences companies as they work to deliver therapeutic innovations to market.